Vicarious Surgical
OTC: RBOTCambridge, US · Founded 2014 · Delaware corporation · 54 employees on LinkedIn · 4 known investors
Find your way into Vicarious Surgical
391 people in our graph share verified history with the Vicarious Surgical team — schools, employers, funds. One of them is your warm intro.
Vicarious Surgical develops a surgical robot for minimally invasive laparoscopic procedures, providing surgeons with 3D visualization and precise control. The system, which has received FDA Breakthrough Device Designation, targets hospitals, surgeons, and patients seeking advanced surgical care.
Also known as Vicarious Surgical Inc.
Founders & leadership
Vicarious Surgical was founded in 2014 by Adam Sachs and Sammy Khalifa.





Board

Investors · 4
Funding
SEC filings, press & company announcements$44.1M disclosed across 6 of 7 rounds · 2016–2025
- Undisclosed amountregistered direct offeringOct 2025Source ↗
▶$13.2MraisedAug 2020 · 6 investors · Other Health CareRule 506(b)
- Sammy KhalifaDirector
- Samir KaulDirector
- Ric FulopDirector
- Philip LiangDirector
- Adam SachsExecutive Officer, Director
- Dror BermanDirector
- Offering amount
- $18.2M
- Amount sold
- $13.2M
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedJan 2019 · 6 investors · Other Health CareRule 506(b)
- Samir KaulDirector
- Sammy KhalifaDirector
- Dror BermanDirector
- Adam SachsExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Jan 2019
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$16.8MraisedMar 2018 · 9 investors · Other Health CareRule 506(b)
- Samir KaulDirector
- Sammy KhalifaDirector
- Adam SachsExecutive Officer, Director
- Dror BermanDirector
- Offering amount
- $16.8M
- Amount sold
- $16.8M
- First sale
- Jan 2018
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$800KraisedOct 2016 · 1 investors · Other Health CareRule 506(b)
- Neil DevaniDirector
- Adam SachsExecutive Officer, Director
- Barry GreeneDirector
- Offering amount
- $800K
- Amount sold
- $800K
- First sale
- Oct 2016
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$1MraisedMay 2016 · 2 investors · Other Health CareRule 506(b)
- Barry GreeneDirector
- Neil DevaniDirector
- Adam SachsExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $1M
- First sale
- May 2016
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$2.4MraisedFeb 2016 · 11 investors · Other Health CareRule 506(b)
- Neil DevaniDirector
- Adam SachsExecutive Officer, Director
- Barry GreeneDirector
- Offering amount
- $2.4M
- Amount sold
- $2.4M
- First sale
- Feb 2016
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Vicarious Surgical is developing a robotic-assisted surgery platform focused on abdominal access and visualization through a single port. The system is designed so that all robotic motion occurs inside the patient's body, entering through a single small incision for the insertion of a camera and two robotic instruments. The company states the system is capable of incision sizes as low as 1.2 cm; currently available disposables require a 1.8 cm incision, and the company is developing disposables intended to require a 1.5 cm incision.
The platform consists of two main components: a patient cart, which interfaces with the patient and facilitates entry of the robot through a single incision while the surgeon retains control of the instrument arms, and a surgeon console, from which the operator drives the robotic instruments and a 3D high-definition camera using proprietary software and hand controllers. The system is also being designed for setup, breakdown, mobility, and storage within medical facilities.
The company describes a staged engineering development path progressing from nine early prototypes to an integrated surgical platform. Vicarious Surgical states that the system's information published on its website represents design goals that have not been evaluated by the FDA other than for the purpose of granting a Breakthrough Device Designation, and that the product is not FDA-cleared and not available for commercial sale in the United States.
▸Full profile — market position, technology, go-to-market, risks & controversies
Market position
Positions itself in robotic-assisted minimally invasive surgery, differentiating on single-port abdominal access, internal articulation and 3D visualization rather than multi-port external robotic arms.
Single-port entry through an incision as small as 1.2-1.5 cm, articulation occurring entirely inside the patient's body, human-inspired arm motion with 28 sensors per arm, 360-degree 3D stereoscopic visualization, and a system designed for mobility, rapid setup and storage in hospital environments.
Technology
The robot is designed to replicate a surgeon's natural upper-body movements from shoulders to elbows to wrists, using 28 sensors per arm. The arms are designed to move in all directions — downward, sideways, upward and backward — with centered pivoting inside the abdomen intended to let the surgeon work from any direction through any entry point. Visualization uses immersive 3D stereoscopic imaging of patient anatomy with responsiveness to the surgeon's movements, delivered via a surgeon console with proprietary software and hand controllers. Placing all robotic motion inside the patient through a single incision is intended to increase freedom of movement and reduce the risk of external instrument collisions around the surgical field.
Go-to-market
Medical facilities and surgical care teams performing robotic-assisted minimally invasive abdominal surgery, with the system positioned around surgeon control and patient recovery outcomes.
Risks & controversies
The system has not been cleared by the FDA and is not for commercial sale in the United States; the company notes that claims on its website represent design goals that have not been evaluated by the FDA aside from evaluations for the purpose of granting a Breakthrough Device Designation. Planned disposables requiring a 1.5 cm incision are still in development.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Founder mafia
3 people who came through Vicarious Surgical went on to found or lead other companies.
Competitors · 5
by search overlapCompanies competing with Vicarious Surgical for the same Google search keywords, organic and paid, via search-intersection analysis.
Legal entities · 1
corporate structureIn the news
▸Research sources · 1
primary sources listed
- Vicarious Surgicalvicarioussurgical.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Vicarious Surgical do?
- Vicarious Surgical is developing a single-port surgical robotic system for minimally invasive abdominal procedures.
- Who founded Vicarious Surgical?
- Vicarious Surgical was founded by Adam Sachs, Sammy Khalifa in 2014.
- Who are Vicarious Surgical's investors?
- Vicarious Surgical's investors include Flucas Ventures, Necessary Ventures, Innovation Endeavors, Khosla Ventures.
- How much funding has Vicarious Surgical raised?
- Vicarious Surgical has disclosed $44.1M raised across 6 of its 7 known rounds.
- Where is Vicarious Surgical headquartered?
- Vicarious Surgical is headquartered in Cambridge, US.









